video

A video on the key strengths and limitations of RCTs and RWE studies plus real-world support for the effectiveness of NINLARO plus lenalidomide and dexamethasone (NRd) in patients with RRMM.

Listen to Dr Andrew Charlton discuss the importance of considering re-treatment of multiple myeloma patients with lenalidomide-based therapies beyond the front-line setting , where they may have been exposed to but not refractory to lenalidomide. Andrew Charlton also discusses the background and some supporting evidence for the two commonly used front-line lenalidomide-based regimens in the UK: front-line therapy in non-transplant eligible patients, in combination with dexamethasone and in a maintenance role in post-ASCT patients.